Navigation Links
Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
Date:10/17/2011

SAN FRANCISCO, Oct. 17, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company's proprietary biochemical protein synthesis technology platform for the synthesis and manufacturing of novel protein therapeutics will be presented at the BioProduction 2011 conference in Berlin.

Trevor Hallam, Ph.D., chief scientific officer of Sutro, will present the capabilities of the company's platform as a design and production tool for hundreds of variants of potential protein therapeutics, including those with site-specifically incorporated non-natural amino-acids as well as those that cannot be synthesized with conventional technologies. Proteins can be expressed at research scale in a rapid parallel manner in several hours, and the linear scalability of the system allows for seamless and prompt scale up for use in clinical studies.  Sutro is establishing a current Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using their biochemical protein synthesis platform that will be on line in the first half of 2012. The featured presentation will take place at 4:20 p.m. CEST on Oct. 20.

"I am pleased to present Sutro's open, cell-free protein synthesis platform and its application to this broad audience at the BioProduction meeting," said Trevor Hallam, Ph.D. "Our technology platform enables the expression of proteins that cannot be expressed with other expression systems, including novel antibody-drug conjugates and other proteins with site-specific modifications. We are currently establishing our own drug pipeline and are also looking forward to discuss potential collaborations with new partners."

About Sutro Biopharma

Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.

Media Contacts:

David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
4. Ondine Biopharma Announces Second Quarter 2008 Financial Results
5. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
6. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
7. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
8. Therapure Biopharma Inc. opens for business with first client contracts
9. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
10. China Biopharma Effects 1 for 100 Reverse Stock Split
11. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... 1, 2016 asking the Federal Drug Administration (FDA) to consider OA as a ... OARSI is concerned about the growing population of OA patients, many of whom ...
(Date:12/6/2016)... December 6, 2016 According to a new ... Material (Polymer, Glass, Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, ... the global market is projected to reach USD 8.78 Billion by ... 19.2% during the forecast period (2016 to 2021). ... ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today ... Alzheimer’s disease (AD) inhibited the direct neurotoxic effect of prion-like forms of ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt with ... cannabis technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal Gold ... past 30 years, Chip Baker other industry veterans have made the evolution of ...
Breaking Biology Technology:
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):